Operationalising exceptional science into successful business
Our founders Kirsty and Tom McCarthy are driven by a shared passion: Operationalising exceptional science into successful business.
Following the 2015 acquisition of Spinifex Pharmaceuticals by Novartis, they founded MTM, a biotechnology ecosystem company specialising in biotech venture creation and integrated support services.
Today we empower biotech ventures to achieve scientific, clinical, and commercial excellence through our discovery and development ecosystem.
Our mission is to create next-generation medicines
We combine our radically collaborative culture and cutting-edge technology to drive continuous innovation and breakthroughs in biotech.
Our purpose is to shape the future of biotech
MTM is dedicated to fostering a culture where agile and expert project teams anticipate trends, lead positive change, and accelerate life-changing medicines to market, benefiting people, payers and society at large.
Key milestones
MTM's journey since inception
Dec 2022
USD $100M raised across the Oxford Pod
Over the threshold with Grey Wolf Therapeutics successful Series B raise of USD $49M
Jan 2023
First Patient Dosed - Grey Wolf Therapeutics
A key milestone on our mission to improve lives, delivering our first drugs from Grey Wolf Therapeutics to patients in clinical trials.
Apr 2024
USD $200M raised across the Oxford Pod
Over the threshold with Pathios Therapeutics successful Series B raise of USD $25M
